Active Filter(s):
Details:
Under the collaboration, University of Oxford and Selvita will advance potential therapeutics in the area of Parkinson's disease and have developed promising prototype compounds that efficiently promote the clearance of alpha-synuclein aggregates.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: University of Oxford
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 05, 2023